For Immediate Release NEW HUMAN DATA STRENGTHENS BIOLOGICAL RATIONALE FOR DMX-200 IN FSGS Highlights • New data presented at Kidney Week 2026 provides additional biological evidence supporting the 1 2 inflammatory mechanism of action of DMX-200 which targets CCR2 in FSGS • Independent...
New Data Supports Biological Rationale for DMX-200 in FSGS
Filed with ASX ·
6ix is reading this filing.
Earlier from Dimerix
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
- First Patient Reaches Four Years in DMX-200 Clinical Program
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- S&P DJI Announces September 2026 Quarterly Rebalance
